TB-500 in the UK: regulatory status

The short answer for anyone researching TB-500 in the United Kingdom: the compound holds no marketing authorisation from the MHRA, it cannot be lawfully sold or supplied for human use under the Human Medicines Regulations 2012^[1], and it is prohibited in sport under the WADA Prohibited List, which UK Anti-Doping enforces^[4]. That position has not changed in the past twelve months.

TB-500 is a grey-market label. Vendors use it for a synthetic heptapeptide (AC-LKKTETQ, corresponding to residues 17 to 23 of thymosin beta-4) and, confusingly, also for the full-length 43-amino-acid thymosin beta-4 protein itself. The science and the trial evidence sit on our TB-500 overview page. This page is about the law in one country. It is for educational and journalistic purposes only. It is not legal or medical advice. If you face a decision with legal or health consequences, speak to a qualified UK solicitor and a healthcare professional who knows your situation.

Table of contents

1. What changed and when 2. No marketing authorisation under the Human Medicines Regulations 2012 3. How the MHRA decides TB-500 is a medicine 4. Import and personal use 5. The WADA S2 prohibition and UK Anti-Doping 6. What we do not yet know 7. Medical and regulatory disclaimer

What changed and when

The most useful thing to say about recent UK changes is that there have not been any specific to TB-500. The compound has never held a UK marketing authorisation, and it does not hold one now. The governing framework, the Human Medicines Regulations 2012, has applied throughout, and no new-drug application for TB-500 or thymosin beta-4 has produced an authorisation in the UK.

The last discrete regulatory event that touched TB-500 directly happened outside UK medicines law and inside sport. The World Anti-Doping Agency added thymosin beta-4 and its derivatives, TB-500 among them, as named examples of prohibited growth factors on the 2018 Prohibited List, effective 1 January 2018^[4]. Before that, TB-500 was caught by the broader wording of the list rather than named on it. The 2018 change removed the ambiguity for athletes. Nothing in the twelve months to mid-2026 has shifted either the medicines position or the sport position in the UK.

No marketing authorisation under the Human Medicines Regulations 2012

UK medicines law runs on a simple rule: a medicinal product needs an authorisation before it can reach the market. Regulation 46 of the Human Medicines Regulations 2012 states that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product, and may not sell or supply a medicinal product otherwise than in accordance with the terms of a UK marketing authorisation or an equivalent registration^[1]. TB-500 has no such authorisation, so any commercial sale or supply of it for human use falls outside what the Regulations permit.

The manufacturing and import side is licensed separately. Regulation 17 provides that a person may not manufacture, assemble or import a medicinal product except in accordance with a manufacturer's licence^[2]. A vendor filling vials of TB-500 for the human market, or bringing them into the country to sell, would need that licence, and the underlying product would still need its own marketing authorisation to be supplied lawfully. Neither exists for TB-500.

None of this makes TB-500 a controlled drug. It is not scheduled under the Misuse of Drugs Act, so it is not a narcotics offence in the way possession of a controlled substance would be. The relevant law is medicines law, and medicines law targets the act of placing an unauthorised product on the market rather than the act of holding a personal quantity. That distinction matters, and we come back to it under personal use.

How the MHRA decides TB-500 is a medicine

A vendor might argue that a vial labelled 'research use only' or 'not for human consumption' sits outside medicines law altogether. UK guidance does not support that reading. The MHRA classifies a product as a medicinal product if it is presented as having properties of preventing or treating disease, or if it may be used with a view to restoring, correcting or modifying a physiological function by pharmacological, immunological or metabolic action^[3]. This is a functional test. It looks at what the substance does and how it is presented, not only at the words printed on the label.

The MHRA guidance is explicit that it weighs the whole presentation of a product, including labelling, packaging, promotional material, websites, social media and customer reviews^[3]. A peptide sold with claims about tendon repair, tissue healing or recovery, or in a vial and reconstitution format that only makes sense as an injectable, is being presented for an effect on human physiology. A disclaimer does not undo that presentation. On the functional test, TB-500 sold to consumers for recovery is a medicinal product, and an unauthorised one.

Import and personal use

The UK operates a narrow personal-import concession for medicines, but it is much narrower than the grey market assumes. It generally applies to a product an individual has been supplied with abroad for their own treatment, carried in personal baggage. It is not a route to order an unauthorised injectable peptide by post from an overseas website. Where a package appears to contain an unlicensed medicine, Border Force and the MHRA can detain it, and the 'research use only' label does not change the analysis once the contents are identified as a medicinal product.

Enforcement in practice concentrates on supply rather than on individual buyers. That is a pattern of enforcement priority, not a statement that personal import is lawful. The prohibition on selling or supplying an unauthorised medicinal product^[1] sits on the seller, and the manufacturer's and importer's licence requirement^[2] sits on the commercial chain. A buyer who imports a vial for personal use is unlikely to be the MHRA's target, but the product remains unauthorised, and a detained parcel can be seized and destroyed with no compensation.

The WADA S2 prohibition and UK Anti-Doping

For anyone who competes, the sport rules are settled and stricter than the ambient legal position. UK Anti-Doping applies the WADA Prohibited List in the United Kingdom, and peptide hormones and growth factors are among the substances prohibited at all times, in and out of competition^[5]. TB-500 falls squarely in that group.

The specific listing is section S2.3, growth factors and growth factor modulators, where thymosin beta-4 and its derivatives, TB-500 included, were added as named examples from 1 January 2018^[4]. There is no therapeutic use exemption pathway in practice, because a TUE requires an approved medical use and a diagnosis that justifies it, and TB-500 has no approved medical use anywhere. An adverse finding for a substance in this category carries a substantial period of ineligibility. For a UK athlete, the sport consequence arrives regardless of how the vial was obtained.

For the cross-country picture and the science behind the compound, see TB-500 regulation by country and the UK regulation hub.

What we do not yet know

Two gaps are worth naming. First, the enforcement detail. Published UK data on how often TB-500 parcels are stopped at the border, and the threshold at which a personal-import case is referred for anything beyond administrative seizure, is not something the MHRA sets out publicly for this substance. The legal position is clear; the operational reality at customs is not documented at that level of granularity.

Second, the evidence base that would ever support authorisation. Outside ophthalmology, where full-length thymosin beta-4 has run human trials as an eye drop, there are no completed Western-standard randomised controlled trials of systemic TB-500 for tendon, ligament or general injury recovery. Without that evidence, no sponsor is in a position to file for a UK marketing authorisation, and the compound's status cannot improve. The detail sits on the TB-500 overview page. What UK law says about TB-500 and what the science says about it currently point the same way: the risk picture is open, and there is no regulated supply to fall back on.

Medical and regulatory disclaimer

This article is for educational and journalistic purposes only and does not constitute medical or legal advice. TB-500 is not an authorised medicine in the United Kingdom. Always consult a qualified healthcare professional before considering any peptide product, and consult a UK solicitor before making any decision with legal consequences. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

This page reflects our understanding of UK regulatory status as of July 2026. Regulations change. Verify current status with the MHRA or qualified legal counsel before acting on anything here. PeptideMethods.com is not a law firm and does not provide legal advice.